UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$336M |
| 2 |
AbbVie
ABBV
|
+$235M |
| 3 |
VMW
VMware, Inc
VMW
|
+$163M |
| 4 |
T-Mobile US
TMUS
|
+$156M |
| 5 |
Aptiv
APTV
|
+$154M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$570M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
Apple
AAPL
|
+$394M |
| 4 |
Abbott
ABT
|
+$262M |
| 5 |
Intel
INTC
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.77% |
| 2 | Healthcare | 13.92% |
| 3 | Consumer Discretionary | 13.52% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
BridgeBio Pharma
BBIO
$16.5B
| $5.77M | ﹤0.01% |
176,951
+8,005
| +5% | +$244K |
|
1027
Bruker
BRKR
$8.14B
| $5.77M | ﹤0.01% |
141,724
-16,598
| -10% | -$653K |
|
1028
National Fuel Gas
NFG
$7.65B
| $5.76M | ﹤0.01% |
137,280
+15,465
| +13% | +$631K |
|
|
RPTX
1029
DELISTED
Repare Therapeutics
RPTX
| $5.73M | ﹤0.01% |
+184,734
| New | +$5.93M |
|
1030
CareTrust REIT
CTRE
$9.74B
| $5.72M | ﹤0.01% |
333,265
+10,396
| +3% | +$182K |
|
1031
NewMarket
NEU
$8.18B
| $5.72M | ﹤0.01% |
14,272
+482
| +3% | +$199K |
|
1032
Urban Edge Properties
UE
$2.73B
| $5.68M | ﹤0.01% |
478,718
-86,259
| -15% | -$866K |
|
1033
Globus Medical
GMED
$11.2B
| $5.67M | ﹤0.01% |
118,771
-9,887
| -8% | -$477K |
|
|
TMX
1034
DELISTED
Terminix Global Holdings, Inc.
TMX
| $5.66M | ﹤0.01% |
158,618
-13,786
| -8% | -$425K |
|
|
P
1035
Everpure Inc
P
$29.9B
| $5.66M | ﹤0.01% |
326,423
+19,074
| +6% | +$286K |
|
1036
Hexcel
HXL
$7.82B
| $5.63M | ﹤0.01% |
124,439
-32,164
| -21% | -$1.14M |
|
1037
Xerox
XRX
$425M
| $5.61M | ﹤0.01% |
366,975
-1,213,518
| -77% | -$20.9M |
|
|
BZUN
1038
Baozun
BZUN
$172M
| $5.6M | ﹤0.01% |
145,592
+4,819
| +3% | +$151K |
|
1039
Macy's
M
$6.68B
| $5.59M | ﹤0.01% |
812,665
-450,413
| -36% | -$2.77M |
|
1040
Paylocity
PCTY
$7.98B
| $5.59M | ﹤0.01% |
38,314
-6,624
| -15% | -$771K |
|
1041
Nutanix
NTNX
$16.9B
| $5.59M | ﹤0.01% |
235,686
-33,640
| -12% | -$697K |
|
|
TCF
1042
DELISTED
TCF Financial Corporation Common Stock
TCF
| $5.55M | ﹤0.01% |
188,617
-2,640
| -1% | -$72.9K |
|
1043
BioCryst Pharmaceuticals
BCRX
$2.4B
| $5.53M | ﹤0.01% |
1,161,155
+1,044,870
| +899% | +$4.17M |
|
1044
Valvoline
VVV
$4.51B
| $5.53M | ﹤0.01% |
286,041
-39,043
| -12% | -$663K |
|
1045
Credit Acceptance
CACC
$6.08B
| $5.49M | ﹤0.01% |
13,098
+59
| +0.5% | +$20.5K |
|
1046
Maximus
MMS
$3.1B
| $5.47M | ﹤0.01% |
77,610
-656
| -0.8% | -$44.1K |
|
1047
OR Royalties Inc
OR
$6.2B
| $5.46M | ﹤0.01% |
547,939
+49,022
| +10% | +$453K |
|
|
WMGI
1048
DELISTED
Wright Medical Group Inc
WMGI
| $5.45M | ﹤0.01% |
183,253
+12,083
| +7% | +$353K |
|
1049
Macerich
MAC
$6.92B
| $5.44M | ﹤0.01% |
606,629
+4,695
| +0.8% | +$36.4K |
|
1050
Armstrong World Industries
AWI
$7.84B
| $5.43M | ﹤0.01% |
69,698
-10,963
| -14% | -$831K |
|
Similar funds
UBS AM's Q2 2020 Portfolio in Review
As of Q2 2020, UBS AM held 2,605 positions worth $164B, up 18% from $139B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
UBS AM withdrew a net $6.16B in Q2 2020, closing 142 positions and reducing 1,290 holdings. Its most notable exit was Allergan plc, an estimated $203M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, UBS AM opened a new position in Otis Worldwide worth $76.5M.
- UBS AM's largest Q2 2020 buy was Otis Worldwide: 1,345,382 shares worth $76.5M.
- UBS AM added most to NetEase in Q2 2020, an estimated $336M increase.
- UBS AM's biggest Q2 2020 reduction was Alibaba, cutting an estimated $570M.
- UBS AM fully exited Allergan plc in Q2 2020, selling an estimated $203M.
- UBS AM's ten largest holdings make up 24% of its $164B portfolio in Q2 2020.
- UBS AM opened 144 new positions and closed 142 in Q2 2020.
- UBS AM's portfolio value rose 18% quarter-over-quarter to $164B.
Based on UBS AM's 13F filing for Q2 2020, filed 14 Aug 2020.